Navigation Links
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Date:3/6/2009

All amounts are in US dollars

QUEBEC CITY, March 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the signing of a development, commercialization and licensing agreement with sanofi-aventis (EURONEXT: SAN; NYSE: SNY) for the development, registration and marketing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market. Cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, is currently in a Phase 3 program in BPH, a non-cancerous enlargement of the prostate, affecting more than 20 million men in the U.S. alone.

Under the terms of the agreement, sanofi-aventis will make an initial $30 million upfront payment to AEterna Zentaris which will also be entitled to receive up to $135 million in additional payments upon achieving certain pre-established regulatory and commercial milestones. Furthermore, AEterna Zentaris will be entitled to receive escalating double-digit royalties on future net sales of cetrorelix for BPH in the United States. Sanofi-aventis will be responsible for the commercialization and booking of sales in the U.S.; however, AEterna Zentaris has retained certain rights to co-promote cetrorelix for BPH in the U.S. market. Finally, sanofi-aventis may perform future Phase 3b and Phase 4 clinical trials, while AEterna Zentaris will have free access to all data for other territories.

"We are delighted to have a partner such as sanofi-aventis who has a proven track record in urology. This partnership marks an important milestone in our quest to bring cetrorelix to market which could provide millions of men with a novel treatment for BPH. Furthermore, this compound could generate sign
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
2. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
5. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
6. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
9. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
11. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 6, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... with Novella Clinical (Novella), to conduct the ... newly diagnosed glioblastoma. Novella is a full-service, global clinical ... to mid-sized oncology companies. The ICT-107 phase 3 trial ... Europe and Canada ...
(Date:7/3/2015)... July 3, 2015 ... verkossa osoitteessa  http://www.openinnovationinscience.at Wienissä ... in Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... (LBG) tekemän, kansainvälisiä tutkijoita ja ... kaksi suurinta haastetta ovat kannustimien ...
(Date:7/3/2015)... , July 3, 2015 ... till 22 september 2015 på  http://www.openinnovationinscience.at ... Innovation in Science" som hålls i ... en färsk undersökning med internationella forskare och ... (LBG) är hälsovetenskapens två största utmaningar bristen ...
(Date:7/3/2015)... July 3, 2015 ... september 2015 på  http://www.openinnovationinscience.at om efteruddannelsesprogrammet ... finder sted i Wien ... af internationale forskere og videnskabsmænd foretaget af ... største udfordringer for sundhedsvidenskaben manglen på incitamenter ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3
... 28 RainDance Technologies, Inc.,a developer of ... of Christopher McNary as President and Chief,Executive ... of the,Board, in driving RainDance Technologies, vision ... Laboratory System in the Life,Sciences and other ...
... &,Instrumentation (CRi) announced today that the United States ... their patent application number,10/669,101, for Spectral Imaging of ... use of multispectral imaging combined,with spectral unmixing to ... living mammal. The unmixing of tissue autofluorescence is,a ...
... 28 Nabi,Biopharmaceuticals (Nasdaq: NABI ) today announced ... will participate in the BMO,Capital Markets Focus on Healthcare ... Broadway Hotel in New York, NY. Dr. Hudson,s,presentation at ... a.m. ET., Dr. Hudson will present a company ...
Cached Biology Technology:RainDance Technologies Appoints McNary President and CEO 2RainDance Technologies Appoints McNary President and CEO 3US Patent and Trademark Office Allows CRi's Patent Application for Spectral Imaging of Deep Tissue 2Nabi Biopharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference 2
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
(Date:6/26/2015)... 26, 2015 ATL Technology, LLC, a top provider ... in single use solutions, headquartered in Springville, Utah ... California corporation with locations in ... Jose, Costa Rica ). This acquisition will ... with ATL Technology,s existing facility in Costa ...
(Date:6/25/2015)...  Imagine a tool specifically designed to help you ... That,s exactly what USANA,s True Health Assessment ... health program provides a personalized approached to measuring your ... lifestyle and nutrition. At the Canadian ... USANA,s THA was honored with the Industry Innovation Award. ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... It makes me sad when an article that should have ... of the student's group in the iGEM competition , check ... their bacterial 'camera'. , Using Petri dishes full of ... The University of Texas at Austin and UCSF successfully created ...
... at the Albert Einstein College of Medicine and the ... is targeted to certain regions of a cell--a process ... wound healing and cancer metastasis. Their study appears in ... Led by Drs. Robert Singer and Dr Stefan Huettelmaier, ...
... researchers has discovered that human embryonic stem cell lines accumulate ... findings do not limit the utility of the cells for ... the researchers say, but draw attention to the need to ... study how these alterations affect the cells' behavior. The researchers' ...
Cached Biology News:Student scientists create living bacterial photographs 2Student scientists create living bacterial photographs 3Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell 2Embryonic stem cells accrue genetic changes 2Embryonic stem cells accrue genetic changes 3Embryonic stem cells accrue genetic changes 4
... pLivSelect is a direct ... recombinant identification. Recombinant selection ... survival, eliminating the need ... This quick and inexpensive ...
... has been designed and created in order ... friendly genotyping analysis tool. We incorporated the ... into the software. Their main requirements were ... low acquisition cost. GeneMarker can perform ...
... through columns is a well-known separation technique ... applications are in DNA/RNA extraction in microbiology, ... purification in chemical or analytical laboratories. ... Genesis series instruments for smaller scales. The ...
... 3D structure visualization, phylogenetic tree building, sequence ... single application. Retrieve ... and filter them in real-time Organize ... searching, filtering and sorting Provides up-to-date ...
Biology Products: